TREVI THERAPEUTICS ($TRVI) posted quarterly earnings results on Tuesday, March 18th. The company reported earnings of -$0.11 per share, beating estimates of -$0.12 by $0.01. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $TRVI stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TREVI THERAPEUTICS Insider Trading Activity
TREVI THERAPEUTICS insiders have traded $TRVI stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TRVI stock by insiders over the last 6 months:
- FARRELL SIMON (Chief Commercial Officer) has made 0 purchases and 2 sales selling 81,313 shares for an estimated $548,877.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
TREVI THERAPEUTICS Hedge Fund Activity
We have seen 69 institutional investors add shares of TREVI THERAPEUTICS stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 4,150,237 shares (+inf%) to their portfolio in Q4 2024, for an estimated $17,098,976
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 3,283,684 shares (+44.5%) to their portfolio in Q4 2024, for an estimated $13,528,778
- SIREN, L.L.C. added 2,906,060 shares (+inf%) to their portfolio in Q4 2024, for an estimated $11,972,967
- WOODLINE PARTNERS LP added 2,606,370 shares (+429.9%) to their portfolio in Q4 2024, for an estimated $10,738,244
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,500,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $10,300,000
- VR ADVISER, LLC removed 2,156,199 shares (-63.0%) from their portfolio in Q4 2024, for an estimated $8,883,539
- VIVO CAPITAL, LLC added 1,875,000 shares (+116.3%) to their portfolio in Q4 2024, for an estimated $7,725,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TREVI THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $TRVI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 10/22/2024
To track analyst ratings and price targets for TREVI THERAPEUTICS, check out Quiver Quantitative's $TRVI forecast page.
TREVI THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $TRVI recently. We have seen 2 analysts offer price targets for $TRVI in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Oren Livnat from H.C. Wainwright set a target price of $6.0 on 10/22/2024
- Mayank Mamtani from B.Riley Financial set a target price of $6.0 on 10/04/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
